Biomaterial Database

Clinical evaluation of lincomycin, a new antibiotic. 1965

B G Byakod, and B T Dave, and O D Gulati, and S D Gokhaie, and B A Sayed

UI	MeSH Term	Description	Entries
D008034	Lincomycin	An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.	Lincolnensin,Lincomycin, (2S-cis)-Isomer,Epilincomycin,Lincocin,Lincomycin A,Lincomycin Hydrochloride,Lincomycin Monohydrochloride,Lincomycin Monohydrochloride, (2S-cis)-Isomer,Lincomycin Monohydrochloride, (L-threo)-Isomer,Lincomycin Monohydrochloride, Hemihydrate,Lincomycin, (L-threo)-Isomer,Hemihydrate Lincomycin Monohydrochloride
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D002648	Child	A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL.	Children
D002701	Chloramphenicol	An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106)	Cloranfenicol,Kloramfenikol,Levomycetin,Amphenicol,Amphenicols,Chlornitromycin,Chlorocid,Chloromycetin,Detreomycin,Ophthochlor,Syntomycin
D002751	Chlortetracycline	A TETRACYCLINE with a 7-chloro substitution.	Aureocyclin,Aureomycin,Aureomycine,Biomycin,Chlorotetracycline,Chlortetracycline Bisulfate,Chlortetracycline Hydrochloride,Chlortetracycline Monohydrochloride,Chlortetracycline Sulfate (1:1),Chlortetracycline Sulfate (2:1),Chlortetracycline, 4-Epimer,Chlortetracycline, Calcium Salt,4-Epimer Chlortetracycline,Bisulfate, Chlortetracycline,Calcium Salt Chlortetracycline,Chlortetracycline, 4 Epimer,Hydrochloride, Chlortetracycline,Monohydrochloride, Chlortetracycline,Salt Chlortetracycline, Calcium
D002986	Clinical Trials as Topic	Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.	Clinical Trial as Topic
D004352	Drug Resistance, Microbial	The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).	Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004917	Erythromycin	A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.	Erycette,Erymax,Erythromycin A,Erythromycin C,Erythromycin Lactate,Erythromycin Phosphate,Ilotycin,T-Stat,Lactate, Erythromycin,Phosphate, Erythromycin,T Stat,TStat
D005260	Female		Females